Infectious Disease Control
Novavax and SK bioscience Expand Manufacturing Agreement
- Novavax secures additional manufacturing capacity through 2022 - SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market GAITHERSBURG, Md., Dec. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializin...
2021-12-24 07:30
3561
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise...
2021-12-23 05:54
3912
World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine
- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emerg...
2021-12-22 09:31
4002
World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine
- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketedby Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports to numerous countri...
2021-12-21 03:33
3507
European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
* Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use inEurope * Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 * Authorization follows positive r...
2021-12-21 03:28
3860
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
* European Commission decision on conditional marketing authorization expected imminently * Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available inEurope GAITHERSBURG, Md., Dec. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NV...
2021-12-20 21:34
3470
Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine
The SPIKEVAX® brand name was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 20, 2021 /PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 v...
2021-12-20 09:00
3881
Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine
* First EUL granted by WHO for a protein-based COVID-19 vaccine * EUL vaccine manufactured and marketed by SII as COVOVAX™ * WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review GAITHERSBURG, Md. and PUNE, India, Dec. 20, 2021 ...
2021-12-20 08:24
4482
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
-- Takeda submits application for TAK-019/NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for NDA, toJapan's Ministry of Health, Labour and Welfare (MHLW) -- Interim data from Phase 1/2 trial in Japan demonstrate robust immune response and favorable tolerability with no serious a...
2021-12-16 12:03
2871
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., Dec. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company's COVID-19 vaccine as a booster for...
2021-12-15 21:58
2989
MGI Contributes to Rapid Detection and Surveillance of COVID-19 Omicron Variant
SHENZHEN, China, Dec. 15, 2021 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, is playing an instrumental role in the global battle against the omicron variant of COVID-19 with its DNBSEQ™ and ATOPlex technologies. As a responsible global company, and as...
2021-12-15 15:49
2179
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-12 18:50
4558
Research shows Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19
SHIJIAZHUANG, China, Dec. 10, 2021 /PRNewswire/ -- "Lianhua Qingwen capsules conferred preventive effects on those exposed to COVID-19", claimed an article titled "Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Tr...
2021-12-10 12:49
3917
MHI RJ Aviation Group and Aero HygenX sign a cooperation agreement for Marketing and Distribution of RAY UV-C Robot
* MHIRJ, the largest Regional MRO in the world, to market RAY product line to CRJ Series operators * RAY UV-C Robot disinfection reduces potential negative impact on aircraft interiors and sensitive equipment * Both RAY and the CRJ Series aircraft are proudly Canadian products OTTAWA, ON...
2021-12-10 08:55
3180
Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...
2021-12-09 20:18
2524
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial Brii Bio is also seeking U.S. FDA Emergency Use Authorization for the amubarvimab/romlusevimab combination DURHAM, N.C. and ...
2021-12-09 06:10
3840
Olay celebrates fearless healthcare frontliners with USD $1.9 million donation as part of a new campaign
SINGAPORE, Dec. 8, 2021 /PRNewswire/ -- Skincare brand, Olay, announced today the launch of a new appreciation campaign for healthcare workers inSingapore as they continue in the battle against COVID-19. As part of the campaign, it has donated USD$1.9 million worth of Olay products to healthcare ...
2021-12-08 19:35
3728
Moscow ranked first among European cities in the ranking of innovations against COVID-19
Moscow ranks third in the world, behind New York and San Francisco MOSCOW, Dec. 7, 2021 /PRNewswire/ -- Moscow is recognized as the first European city in the ranking of innovations, that are used for the formation of resilience to the coronavirus. It is ahead ofLondon and Barcelona. The Russian...
2021-12-07 02:34
4560
RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of conce...
2021-12-06 20:01
4389
Brii Biosciences Included in Hong Kong Stock Connect
DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-06 10:54
4250
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 314 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7342
GAC Energy Releases 2025 EV Charging Ecosystem Report: Over 23,000 Self-Operated Charging Piles Across China
2026-01-17 10:59
5866
